Heart diseases are the most common cause of maternal death during pregnancy in Western countries. The current ESC guidelines 2018 for the management of cardiovascular diseases during pregnancy is a guide for any physician facing the challenge of caring for pregnant women with cardiovascular diseases. Among the new concepts compared to 2011, are recommendations to classify maternal risk due to the modified World Health Organization (mWHO) classification, introduction of the pregnancy heart team, guidance on assisted reproductive therapy, specific recommendations on anticoagulation for low-dose and high-dose requirements of vitamin K antagonists and the potential use of bromocriptine in peripartum cardiomyopathy. The Food and Drug Administration (FDA) categories A–D and X should no longer be used. Therefore, the table of drugs was completed with detailed information from animal and human studies on maternal and fetal risks. The new findings on specific heart diseases are presented in detail in the respective chapters.

Additional Metadata
Keywords Congenital heart diseases, Heart failure, Heart valve diseases, Hypertension, Risk assessment
Persistent URL dx.doi.org/10.1007/s00059-018-4765-4, hdl.handle.net/1765/112548
Journal Herz: kardiovaskulaere Erkraenkungen
Citation
Seeland, U, Bauersachs, J, Roos-Hesselink, J.W, & Regitz-Zagrosek, V. (2018). Update 2018 der ESC-Leitlinie zu kardiovaskulären Erkrankungen in der Schwangerschaft: Die wichtigsten Fakten. Herz: kardiovaskulaere Erkraenkungen, 43(8), 710–718. doi:10.1007/s00059-018-4765-4